Interestingly, SFN alters the CDK-cytolytic protein axis, P19 and P27, and the expression of CD44 variations in prostate cancer cells, prompting cell cycle arrest in the S and G2/M phases and suppressing growth and proliferation (Rutz et al. 2020). Here, SFN is linked to prostate carcinoma.